Mukai Itsumi, Yoshizawa Taku, Kumagai Junko, Takahashi Naoko, Tsuchiya Shinichiro
Department of Pharmacy, Omachi Tsuchiya Clinic, Hiroshima, Japan.
Ther Apher Dial. 2014 Jun;18 Suppl 1:28-33. doi: 10.1111/1744-9987.12205.
We conducted a questionnaire survey of 79 maintenance hemodialysis patients switching lanthanum carbonate (LC) formulation from chewable tablets to granules, to investigate the compliance and patient preferences of these two formulations. For the number of times chewed when taking chewable tablets, the ratio of patients who responded 10 times or more was 54.4%, who responded four to nine times was 24.1% and who responded three times or less was 8.9%. Thirty-seven patients (46.8%) responded "Granules are easier to take", 22 patients (27.8%) responded "Chewable tablets are easier to take", and 20 patients (25.3%) responded "No difference between formulations." Changes in serum phosphorus (P) levels were also measured for 4 weeks after switching formulation, but no significant differences were observed before and after switching. We think that these questionnaire survey results show the compliance status and the patient needs for LC in the clinical practices.
我们对79例将碳酸镧(LC)制剂从咀嚼片换成颗粒剂的维持性血液透析患者进行了问卷调查,以调查这两种制剂的依从性和患者偏好。对于服用咀嚼片时的咀嚼次数,回答10次及以上的患者比例为54.4%,回答4至9次的为24.1%,回答3次及以下的为8.9%。37例患者(46.8%)回答“颗粒剂更易服用”,22例患者(27.8%)回答“咀嚼片更易服用”,20例患者(25.3%)回答“两种制剂无差异”。在更换制剂后还测量了4周的血清磷(P)水平变化,但更换前后未观察到显著差异。我们认为这些问卷调查结果显示了临床实践中LC的依从性状况和患者需求。